Winter Matthew C, Hancock B W
Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, University of Sheffield, UK.
Expert Opin Drug Saf. 2009 Mar;8(2):223-35. doi: 10.1517/14740330902750114.
Rituximab, a chimeric mouse/human monoclonal antibody targeting the pan-B-cell antigenic marker CD20, was the first monoclonal antibody licensed for use in the treatment of cancer.
This review focuses on the impact of rituximab in the treatment of patients with B-cell non-Hodgkin lymphoma (NHL).
Three key areas related to the use of rituximab in B-cell NHL are discussed: mechanism of action, clinical efficacy in both indolent and aggressive disease, and safety of its use as both monotherapy and in combination with chemotherapy.
RESULTS/CONCLUSIONS: Rituximab has demonstrated significant clinical efficacy in the treatment of NHL, particularly in combination with chemotherapy, and its use has revolutionized the treatment of both indolent and aggressive B-cell NHL over the past decade. Furthermore, consistent toxicity data have been obtained with a safe and tolerable profile in most patients.
利妥昔单抗是一种靶向泛B细胞抗原标志物CD20的嵌合型鼠/人单克隆抗体，是首个被批准用于癌症治疗的单克隆抗体。
本综述聚焦于利妥昔单抗在B细胞非霍奇金淋巴瘤（NHL）患者治疗中的影响。
讨论了与利妥昔单抗在B细胞NHL中使用相关的三个关键领域：作用机制、在惰性和侵袭性疾病中的临床疗效以及作为单药治疗和与化疗联合使用时的安全性。
结果/结论：利妥昔单抗在NHL治疗中已显示出显著的临床疗效，尤其是与化疗联合使用时，在过去十年中，其应用彻底改变了惰性和侵袭性B细胞NHL的治疗方式。此外，已获得一致的毒性数据，大多数患者的安全性和耐受性良好。
